Hypovolemic shock - Pipeline Insight, 2024

This “Hypovolemic shock Pipeline Insight, 2024,” report provides comprehensive insights about companies and pipeline drugs in Hypovolemic shock pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hypovolemic shock Understanding

Hypovolemic shock: Overview

Hypovolemic shock is a life-threatening condition that results when you lose more than 20 percent (one-fifth) of your body’s blood or fluid supply. This severe fluid loss makes it impossible for the heart to pump a sufficient amount of blood to the body. Hypovolemic shock can lead to organ failure. This condition requires immediate emergency medical attention. The most common cause of hypovolemic shock is blood loss when a major blood vessel bursts or when a person is seriously injured. This is called hemorrhagic shock.

Symptoms
The symptoms of hypovolemic shock vary with the severity of the fluid or blood loss. Although, all symptoms of shock are life-threatening and need emergency medical treatment. Internal bleeding symptoms may be hard to recognize until the symptoms of shock appear, but external bleeding will be visible. Other signs of hypovolemic shock include:

• Rapid heartbeat
• Quick, shallow breathing
• Feeling weak
• Being tired
• Confusion or wooziness
• Low blood pressure
• Cool, clammy skin

Diagnosis
A physical examination can reveal signs of shock, such as low blood pressure and rapid heartbeat. In addition to physical symptoms, your doctor may use a variety of testing methods to confirm that a person is experiencing hypovolemic shock. These include: blood testing to check for electrolyte imbalances, kidney, and liver function, ultrasound of the heart, electrocardiogram to assess heart rhythm, and right heart catheterization to check how effectively the heart is pumping.

Treatment
Treatment revolves around controlling loss of fluid and blood, replacing what’s been lost, and stabilizing damage that both caused and resulted from the hypovolemic shock. This will also include treating the injury or illness that caused the shock, if possible. These include: blood plasma transfusion, platelet transfusion, red blood cell transfusion, intravenous crystalloids. Doctors may also administer medications that increase the heart’s pumping strength to improve circulation and get blood where it’s needed. These include: dopamine, dobutamine, epinephrine, and norepinephrine.

Hypovolemic shock Emerging Drugs Chapters

This segment of the Hypovolemic shock report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypovolemic shock Emerging Drugs

PMZ-2010 (Centhaquine): PharmazzPMZ-2010 (Centhaquine) acts through a unique mechanism of action that is completely different from any of the existing drugs or investigational products. It is NOT a vasopressor, however, it increases blood pressure and cardiac output by augmenting venous blood return to the heart (alpha2B-adrenergic stimulation), and it enhances tissue perfusion by arterial dilatation (alpha1-adrenergic block). Enhancing tissue perfusion is a significant advantage in reducing the adverse effects of existing vasopressors. Moreover, it does not act on beta-adrenergic receptors, and therefore the risk of arrhythmias is mitigated. Marketing authorization received from Indian regulatory agency.

Hypovolemic shock: Therapeutic Assessment

This segment of the report provides insights about the different Hypovolemic shock drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hypovolemic shock

There are approx. 1+ key companies which are developing the therapies for Hypovolemic shock. The companies which have their Hypovolemic shock drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Pharmazz and others.

Phases

This report covers around 1+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hypovolemic shock pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypovolemic shock: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypovolemic shock therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypovolemic shock drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hypovolemic shock R&D. The therapies under development are focused on novel approaches to treat/improve Hypovolemic shock.

Hypovolemic shock Report Insights

• Hypovolemic shock Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hypovolemic shock Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hypovolemic shock drugs?
• How many Hypovolemic shock drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypovolemic shock?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypovolemic shock therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hypovolemic shock and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pharmazz

Key Products

• PMZ-2010

This product will be delivered within 2 business days.